Real-world use of nemolizumab for adults with prurigo nodularis
Part of Skin clinical trials.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate-to-severe prurigo nodularis
- Your doctor has decided to start you on nemolizumab (Nemluvio) for your condition
- You have not taken nemolizumab before
- You have not used any experimental drug in the last 3 months
- You are able to understand the study information and fill out questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This study tests whether a drug called lebrikizumab can reduce severe itching and skin bumps caused by prurigo nodularis (a chronic skin condition). The drug works by calming an overactive immune response in the skin.
Hear when a new Prurigo Nodularis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.